In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold 500 shares of the company's common stock. The shares were sold at a price of $240.00 each, totaling $120,000. Following this sale, David retains ownership of 5,741 shares in the company.
The transaction, executed on January 21, 2025, was carried out under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which was adopted by David on September 5, 2024. This type of plan allows executives to set up a predetermined schedule for buying or selling company stock, helping to avoid potential conflicts of interest. The $69.71B market cap healthcare company has maintained dividend payments for 54 consecutive years, with InvestingPro analysis revealing 10+ additional key insights about BDX's financial health and market position.
In other recent news, Becton Dickinson (BD), a global medical technology company, posted strong financial results in its Fourth Quarter and Full-Year Fiscal 2024 Earnings Call. The company reported Q4 revenue growth of 7.4%, a full-year organic revenue increase of 5%, and a rise in adjusted diluted earnings per share (EPS) by 11.4%, reaching $13.14 for the full year. Despite challenges in China and modest growth in the Bioscience-Pharma sector, BD's MedTech and Diagnostics segments grew by 5.9%, with BD Medical (TASE:PMCN)'s biologic drug delivery sales surpassing $1 billion.
In other recent developments, BD announced a $1 billion share repurchase plan and increased its dividend by 9.5%. Anticipating high single-digit revenue growth for FY '25, the company expects revenue between $21.9 billion and $22.1 billion, with adjusted diluted EPS guidance of $14.25 to $14.60. However, the company remains cautious about the Chinese market, expecting a mid-single-digit decline due to value-based procurement pressures.
BD aims for a 100 basis point increase in operating margins and a stronger second half of FY '25. The company is optimistic about the continued growth of key products such as Alaris into FY '25 and expects innovations in biologics and diagnostics to drive growth, along with the integration of the Advanced Patient Monitoring business. These are the recent developments in the company's performance and strategic outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.